MA06.08 Real-World Landscape Analysis of Activating ERBB2/ERBB3 Alterations in 107,561 Tissue and Plasma Samples from Patients with NSCLC

Multiple HER2 targeted therapies have been studied in NSCLC carrying ERBB2 amplification or mutations with variable results. Fam-trastuzumab-deruxtecan-nxki (T-DXd) is approved for NSCLC with activating ERBB2 mutations. We studied the landscape of ERBB2/ERBB3 alterations from both FoundationMedicine (FMI) and MemorialSloanKettering Cancer Center (MSK) sequencing cohorts and the use of HER2 targeted therapies for mutations excluded from the registrational trials of T-DXd approval.